MIRA Pharmaceuticals publishes peer-reviewed study on obesity drug candidate

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced the publication of a peer-reviewed manuscript describing preclinical findings for SKNY-1, its oral investigational drug candidate for obesity and nicotine addiction, in the International Journal of Molecular Sciences.

The study, conducted in an MC4R-deficient zebrafish model, demonstrated that SKNY-1 produced dose-dependent weight reduction, with the higher dose group showing approximately 30% reduction relative to baseline after six days of oral administration. The compound also reduced total cholesterol, low-density lipoprotein, and hepatic triglyceride accumulation compared to untreated controls.

According to the publication, SKNY-1 demonstrated differential engagement of cannabinoid receptor 1 signaling pathways, partial agonist activity at cannabinoid receptor 2, and selective inhibition of monoamine oxidase B relative to MAO-A. The study reported dose-dependent attenuation of compulsive feeding and nicotine-seeking behaviors in multiple behavioral tests.

"We believe the publication of these peer-reviewed findings further supports the differentiated pharmacological profile of SKNY-1 and its potential as a novel oral investigational approach targeting both metabolic and reward-associated pathways," said Erez Aminov, CEO of MIRA.

The zebrafish model showed no significant reduction in whole-body density during the treatment period. The compound also modulated appetite-regulatory leptin and ghrelin gene expression patterns toward wild-type levels.

MIRA noted that the publication describes short-term preclinical findings in zebrafish models and that additional studies, including mammalian studies, pharmacokinetic evaluations, and toxicology studies, will be required before determining whether SKNY-1 may advance toward clinical development. The compound has not been approved by regulatory authorities and its safety and efficacy have not been established in humans.

You May Also Be Interested In

• Takeda names Julie Kim as president and CEO after shareholder vote
• Goldman Sachs Starts Twilio (TWLO) at Buy
• Goldman Sachs Assumes Braze Inc (BRZE) at Buy